JavaScript is NOT enabled !

Please enable JavaScript.

Article

PubMed

This record comes from PubMed

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT

Bone marrow transplantation. 2015 Mar ; 50 (3) : 341-7. [epub] 20141117

Bone Marrow Transplant
ISSN 1476-5365 | 0268-3369
Source

Language English Country Great Britain, England Media print-electronic

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link https://www.medvik.cz/link/pmid25402418

PubMed 25402418
DOI 10.1038/bmt.2014.262
PII: bmt2014262
Knihovny.cz E-resources

MeSH
Leukemia, Myeloid, Acute blood therapy MeSH
Antigens, CD34 metabolism MeSH
Transplantation, Autologous MeSH
Adult MeSH
Remission Induction MeSH
Middle Aged MeSH
Humans MeSH
Adolescent MeSH
Young Adult MeSH
Hematopoietic Stem Cell Mobilization methods MeSH
Disease-Free Survival MeSH
Transplantation Conditioning methods MeSH
Recurrence MeSH
Risk Factors MeSH
Hematopoietic Stem Cell Transplantation methods MeSH
Bone Marrow Transplantation methods MeSH
Check Tag
Adult MeSH
Middle Aged MeSH
Humans MeSH
Adolescent MeSH
Young Adult MeSH
Male MeSH
Female MeSH
Publication type
Journal Article MeSH
Research Support, Non-U.S. Gov't MeSH
Randomized Controlled Trial MeSH
Names of Substances
Antigens, CD34 MeSH

The faster hematopoietic recovery after autologous peripheral blood SCT (APBSCT) in patients with AML may be offset by an increased relapse risk as compared with autologous BMT (ABMT). The EORTC and GIMEMA Leukemia Groups conducted a trial (AML-10) in which they compared, as second randomization, APBSCT and ABMT in first CR patients without an HLA compatible donor. A total of 292 patients were randomized. The 5-year DFS rate was 41% in the APBSCT arm and 46% in the ABMT arm with a hazard ratio (HR) of 1.17; 95% confidence interval=0.85-1.59; P=0.34. The 5-year cumulative relapse incidence was 56% vs 49% (P=0.26), and the 5-year OS 50% and 55% (P=0.6) in the APBSCT and ABMT groups, respectively. APBSCT was associated with significantly faster recovery of neutrophils and platelets, shorter duration of hospitalization, reduced need of transfusion packed RBC and less days of intravenous antibiotics. In both treatment groups, higher numbers of mobilized CD34+ cells were associated with a significantly higher relapse risk irrespective of the treatment given after the mobilization. Randomization between APBSCT and ABMT did not result in significantly different outcomes in terms of DFS, OS and relapse incidence.

A O R N San Giuseppe Moscati Avelino Italy

CHU Lyon France

CHU Sart Tilman Liège Belgium

EORTC Headquarters Brussels Belgium

Federico 2 University Napoli Italy

GIMEMA Data Center Roma Italy

Gustave Roussy Comprehensive Cancer Center Villejuif France

Hôtel Dieu Paris France

Institute Hematology Prague Czech Republic

Leiden University Medical Center Leiden The Netherlands

Necker Institut Curie Paris France

Ospedale Civile Pescara Italy